• Home
  • Stages
    • Late Discovery
    • Early Development
    • Late Development & Commercialization
    • Lifecycle Management
  • Services
    • Project Leadership & Business Solutions
    • Late Discovery & Investigative Research
    • Chemistry, Manufacturing & Controls (API & Drug Product)
    • Nonclinical Sciences
    • Clinical Strategy
    • Regulatory Strategy & Application Preparation
    • Quality & Compliance
    • Advanced Technologies
  • Leadership
  • News
  • Careers
  • Contact
  • Home
  • Stages
    • Late Discovery
    • Early Development
    • Late Development & Commercialization
    • Lifecycle Management
  • Services
    • Project Leadership & Business Solutions
    • Late Discovery & Investigative Research
    • Chemistry, Manufacturing & Controls (API & Drug Product)
    • Nonclinical Sciences
    • Clinical Strategy
    • Regulatory Strategy & Application Preparation
    • Quality & Compliance
    • Advanced Technologies
  • Leadership
  • News
  • Careers
  • Contact

 

Roger Nosal, Head of Global Regulatory Strategy and Submissions

Roger NosalRoger Nosal is Principal Consultant with Roger Nosal PharmaCMC Regulatory Consultants. Prior to September 2022 he was Vice President & Head of Global Chemistry, Manufacturing & Controls at Pfizer where he was accountable for development, preparation & prosecution of global regulatory CMC applications for new commercial products & investigational applications (small & large molecules, combination products, vaccines including the COVID-19 mRNA vaccines and gene/cell therapies).

Roger is currently Rapporteur for the ICH QDG and has served as PhRMA representative to several ICH EWG & IWGs. Roger was instrumental in development & implementation of Quality by Design & was awarded the Pharmaceutical Discovery, Development and Manufacturing Forum Award from AIChE for outstanding contributions to advancing QbD in 2013. He has been an invited speaker/expert panelist (>230) on a myriad of CMC development/regulatory topics including technical innovations (continuous manufacturing, PAT & adaptive controls).

Expertise:

  • Contributed to the evolution of Quality by Design & has advocated for global regulatory harmonization through several ICH, PhRMA, ISPE, PQRI, AAPS, IFPAC, ACS & DIA technical committees.
  • Roger’s 41 years of experience at G. D. Searle, Monsanto, Pharmacia & Pfizer, includes 27 years in regulatory affairs & 13 as a Medicinal & Process Chemist and author of 24 patents.


  • [email protected]

  • Terms of Use
  • Privacy Policy
  • Copyright Policy
  • 2023 © Copyright NGT BioPharma Consultants

860.333.9023 · [email protected]